Skip to main content
Fig. 1 | Cancer Cell International

Fig. 1

From: Reversible inhibitor of CRM1 sensitizes glioblastoma cells to radiation by blocking the NF-κB signaling pathway

Fig. 1

S109 combined with radiotherapy significantly inhibited GBM cell proliferation. U87 a and C6 b cell lines were treated with varying doses of S109, and cell viability was assessed by CCK-8 assay at 72 h after treatment. c, e Measurement of anti-proliferation effects of S109 and/or IR by EdU incorporation assay. Represent images were showed. The EdU incorporation rate was presented as the ratio of EdU positive cells to total DAPI positive cells, scale bar: 100 μm. d, f Quantification of the percentage of EdU-positive cells. All the results were presented as the mean ± SD from 3 independent experiments, *P < 0.05, **P < 0.01, ***P < 0.001

Back to article page